Compare · ABBV vs ENVB
ABBV vs ENVB
Side-by-side comparison of AbbVie Inc. (ABBV) and Enveric Biosciences Inc. (ENVB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ENVB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $449.63B, about 83293.4x ENVB ($5.4M).
- Over the past year, ABBV is up 34.5% and ENVB is down 91.6% - ABBV leads by 126.1 points.
- ABBV has been more active in the news (23 items in the past 4 weeks vs 1 for ENVB).
- ABBV has more recent analyst coverage (25 ratings vs 3 for ENVB).
- Company
- AbbVie Inc.
- Enveric Biosciences Inc.
- Price
- $254.52+0.06%
- $1.33-2.92%
- Market cap
- $449.63B
- $5.4M
- 1M return
- +14.38%
- -3.62%
- 1Y return
- +34.48%
- -91.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 23
- 1
- Recent ratings
- 25
- 3
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Enveric Biosciences Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. It has a pipeline of development programs for radiodermatitis, glioblastoma multiforme, pruritus, rashes, and dry skin and chemotherapy-induced neuropathy. The company is headquartered in Naples, Florida.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest ENVB
- Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Enveric Biosciences Announces Participation in 2026 BIO International Convention
- Enveric Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Enveric Biosciences Inc.
- Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
- Chief Financial Officer Coveney Kevin Michael was granted 133,333 shares, increasing direct ownership by 281% to 180,746 units (SEC Form 4)
- Chief Executive Officer Tucker Joseph Edward was granted 201,124 shares, increasing direct ownership by 286% to 271,479 units (SEC Form 4)
- Director Pasqualone Frank was granted 18,518 shares, increasing direct ownership by 234% to 26,423 units (SEC Form 4)
- Director Webb Michael D was granted 18,518 shares, increasing direct ownership by 234% to 26,416 units (SEC Form 4)
- Director Schabacker Marcus was granted 18,518 shares, increasing direct ownership by 234% to 26,418 units (SEC Form 4)